PET/CT-based radiomics analysis may help to predict neoadjuvant chemotherapy outcomes in breast cancer.

ABSTRACT:

Background

The aim of this study was to evaluate the clinical usefulness of radiomics signature-derived ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) positron emission tomography-computed tomography (PET-CT) for the early prediction of neoadjuvant chemotherapy (NAC) outcomes in patients with (BC).

Methods

A total of 124 patients with BC who underwent pretreatment PET-CT scanning and received NAC between December 2016 and August 2019 were studied. The dataset was randomly assigned in a 7:3 ratio to either the training or validation cohort. Primary tumor segmentation was performed, and radiomics signatures were extracted from each PET-derived volume of interest (VOI) and CT-derived VOI. Radiomics signatures associated with pathological treatment response were selected

SUBMITTER: Yang L 

PROVIDER: S-EPMC9676961 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature